AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04670159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information With Brochure
Description: An e-brochure will be prepared for students in this group to provide information on ergonomics, physical activity and exercise. and the e-brochure will be sent to the students via e-mail after the initial evaluation.
Study NCT02327611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol
Study NCT02327611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Ringer's lactate solution
Study NCT00617812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shan5
Description: Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
Study NCT03754218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amnion Membrane Powder
Description: This sterilized product is composed of lyophilized, gamma-irradiated powder made from amniotic membrane for topical application with the purpose of enhanced wound healing.
Study NCT03754218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SOC Wound Covering
Description: Institutional standard of care wound covering.
Study NCT03754218 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SOC Wound Covering
Description: Institutional standard of care wound covering.
Study NCT01965119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
Study NCT02682446 — intervention group
Intervention type: DRUG
Intervention: H pylori eradication
Description: The regimen of H. pylori eradication was like that: 1-week conventional proton pump inhibitor (PPI) based triple therapy (lansoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for a week) after confirmation of H. pylori infection. If the participants who initially failed to respond to the first eradication, they recommended to underwent second-line eradication therapy with the regimen of 7-day bismuth containing quadruple regimen \[lansoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate (Denol; Greencross Co., Seoul, Korea) 300 mg q.i.d. (three tablets 30 min before meals and one tablet 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. for 1 week\]
Study NCT03131206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: * Oral, BID~* Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~* Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days.
Study NCT02960269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interprofessional back pain assessment
Description: team assessment and education with urban physical therapist and rural nurse practitioner via telehealth
Study NCT00860353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2551
Description: Single dose of oral solution.
Study NCT00860353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of oral solution
Study NCT03342560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonographic SWE measurements with 4 different ultrasound systems
Description: Sonographic Shear wave elastography will be performed to quantify liver fibrosis
Study NCT02665260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cantharidin
Description: cantharidin 0.7% topical liquid
Study NCT02665260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: cantharidin 0.7% topical liquid
Study NCT02665260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical liquid
Study NCT02665260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze occlusion bandage
Description: Gauze occlusion bandage with adhesive tape
Study NCT02665260 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Gauze occlusion bandage
Description: Gauze occlusion bandage with adhesive tape
Study NCT04068805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
Study NCT04747392 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: SAL001
Description: administrated once by subcutaneous injection
Study NCT04747392 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FORSTEO
Description: administrated once by subcutaneous injection
Study NCT03923491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Feeding, Healthy Eating
Description: Home Based Motivational Interviewing to Improve Diet Quality of Preschoolers
Study NCT03923491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading Readiness
Description: Active Control that uses Motivational Interviewing to improve Reading Readiness of Preschool Children
Study NCT02433795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine plus rituximab
Description: Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle
Study NCT03499236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Wave Interatrial Shunt
Description: The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovalis and straddles the interatrial septum.
Study NCT03499236 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Right heart catheterization, invasive echocardiography.
Study NCT01221779 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intensive language therapy
Description: 2 weeks of daily computerized naming training, daily, 3 hours
Study NCT01221779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive language therapy
Description: 2 weeks of daily computerized naming training, daily, 3 hours
Study NCT03990272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIT drops
Description: once a day
Study NCT03990272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo drops
Description: once a day
Study NCT01976910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM-CHOC-PEN
Description: DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued.
Study NCT00814346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGb761®
Description: Four weeks for AD patients, 18 months for MC and CNE patients
Study NCT00814346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet BID
Study NCT01886625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unilateral single-port VATS sympathicotomy
Study NCT04551781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 Mg Prednisone for 14 days
Description: 20 Mg Prednisone for 14 days
Study NCT04551781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: symptomatic ttt
Study NCT00816049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6MPindividualized
Description: Oral 6-mercaptopurine with a starting dose of 25 mg/m2 and upward adjusted in steps of 25 mg/m2 (i.e. 50 or 75 mg/m2) if unacceptable bone-marrox toxicity is not encountered
Study NCT00816049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6MPfixed
Description: Oral 6-mercaptopurine at a fixed dose of 25 mg/m2 treatment days 30-85
Study NCT02571387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Study NCT02571387 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham meditation
Study NCT04143126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy
Description: An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
Study NCT04143126 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Supportive Therapy
Description: An 18-month intervention that uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
Study NCT03105219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
Study NCT03105219 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
Study NCT02279017 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mHealth Texting for Weight Loss
Study NCT00587925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone Mineral Density
Description: Clinic visits twice during the first 2 years of the study with medical care directed by your treating doctor.BMD is measured by an X-ray test. The most common type of BMD testing is by energy x-ray absorptiometry (DEXA). Usually BMD is measured every other year, but to closely monitor women on this study, the BMD will be evaluated more often. The BMD will be measured 3 times (baseline, 12 months and 24 months) on this study. Study blood work is obtained three times (baseline, 6 months, and 12 months). Blood (about 3 teaspoons).
Study NCT01806454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Study NCT05390736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait and balance assessment
Description: Patients are given Time Up and Go (TUG) tests, 30-second chair test, and 4-stage balance test (side-by-side, instep, tandem, and one foot).
Study NCT05390736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication review
Description: Patients' medication history in the EHR is assessed for polypharmacy (using 5 or more medications concurrently) and use of medication in the following classes: tricyclic antidepressants, antihistamines, antiemetics, antipsychotics, antispasmotics, muscle relaxants, benzodiazepines, hypnotics, and opioids. The CRN confirms prescriptions with the patient. The CRN reports the medication risk in her provider report and provides medication management educational materials to the patient. At the patient's upcoming primary care visit, providers evaluated whether the medications associated with increased fall risk could be adjusted.
Study NCT04068805 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
Study NCT05390736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comorbidity review
Description: The clinical research nurse reviews the patient's EHR problem list for diagnoses of comorbidities associated with increased fall risk including: cognition problems, Parkinson's disease, cardiac issues, depression, or incontinence. Comorbidities are shared with providers in the recommendation statement.
Study NCT05390736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fall history
Description: The CRN asks how many times the patient had fallen in the past 12 months, whether those with falls sought medical attention, and if they experienced blackouts, loss of consciousness, or a broken/fractured bone(s) resulting from a fall. Fall history information is added to the provider report to increase the salience of fall prevention information.
Study NCT05390736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of feet/footwear
Description: The CRN observes or asks about the patient's current footwear, asks about foot pain or loss of sensation, and notes a diabetes diagnosis when applicable. Patient reports of foot pain, loss of sensation or diabetes result in a CRN note to the provider to examine the patient's feet and the potential need for a referral to podiatry. The CRN also reviewed a safe footwear handout with all patients regardless of their responses and emailed it to patients with other patient information following the call.
Study NCT05390736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of visual acuity
Description: The CRN projects a Banner eye chart on Zoom for the patient to read with their contacts or glasses from five feet away for both eyes together and each eye individually. Phone patients are asked to self-report any vision problems. If either the video screening or patient self-report indicated any vision problems, the CRN notes the result and recommendation for eye care referral for the patient's provider to review and order.
Study NCT05390736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home safety risk assessment
Description: The CRN reviews the CDC brochure Check for Safety: A Home Fall Prevention Checklist for Older Adults with each patient. Check for Safety asks 17 questions about the home's floors, stairs and steps, kitchen, bathrooms, and bedrooms and suggests ideas for removing or reducing fall hazards. The CRN communicates home safety risks and a recommendation for occupational therapy to the provider for indicated patients.
Study NCT05390736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vitamin D Deficiency
Description: The CRN asks the patient if they usually take a Vitamin D supplement with their other medications. If the patient does not take a Vitamin D supplement, the CRN recommends the provider check Vitamin D levels and consider supplementation if Vitamin D levels are less than 20 ng/mL.
Study NCT04023916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab-R-CHOP
Description: Drug:Sintilimab:~Sintilimab:200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 200 mg IV on Day 1 of Cycles 9-14.~Drug: Rituximab Rituximab:Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m\^2 IV on Day 1 of Cycle 1-8, during induction treatment.~Drug: Cyclophosphamide Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Doxorubicin Hydrochloride Liposome Injection Doxorubicin Hydrochloride Liposome Injection will be administered at a dose of 35 mg/m\^2 IV on Day 2-3 of Cycle 1-6, during induction treatment.~Drug: Vincristine Vincristine will be administered at a dose of 1.4 mg/m\^2 (maximum 2 mg) IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Prednisone Prednisone will be administered at a dose of 40 mg/m\^2 orally on Days 1-5 of Cycle 1-6, during induction treatment. Prednisolone may be given if prednisone is unavailable.
Study NCT02536430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: One group received a buccal infiltration of Ketorolac Tromethamine
Study NCT00360737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)
Description: Biological/Vaccine NP-018 (heptavalent equine-derived botulinum antitoxin) is prepared from pooled plasma obtained from horses that have been immunized against one of seven botulinum antitoxins (A-G). .
Study NCT02507440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
Study NCT02507440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
Study NCT02507440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: All patients will receive intravenous propofol as anesthesia for EGD
Study NCT02507440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: All patients will receive intravenous propofol as anesthesia for EGD
Study NCT00956787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)
Description: Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
Study NCT01376310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: up to 2 mg/day
Study NCT02536430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: buccal infiltration of Normal Saline.
Study NCT03575819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR46
Description: FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
Study NCT01376310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + GSK1120212
Description: dose as defined in the dose escalation protocol.
Study NCT01376310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib + GSK1120212
Description: dose as defined in the dose escalation protocol.
Study NCT01376310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed + GSK1120212
Description: dose as defined in the dose escalation protocol
Study NCT01376310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + GSK1120212
Description: dose as defined in the dose escalation protocol
Study NCT01376310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel + GSK1120212
Description: dose as defined in the dose escalation protocol
Study NCT01376310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + GSK1120212
Description: dose as defined in the dose escalation protocol
Study NCT01376310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus + GSK1120212
Description: dose as defined in the dose escalation protocol
Study NCT01849016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Study NCT01849016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04815395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Administration of oxytocin (24IU) orally
Study NCT04815395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Administration of oxytocin (24IU) intranasally
Study NCT04815395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo orally
Study NCT06082297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chattanooga Physio, DJO, neuromuscular electrical stimulation
Description: Neuromuscular electrical stimulation (NMES) was applied with a device called Chattanooga Physio (DJO), testing 10 different combinations of parameter-settings. The parameter-settings that were varied and combined were frequency (1Hz and 36Hz) and plateau times (0.5s, 1.5s, 3s, 5s, 7s). The NMES was applied to the calf of the participants via transversally placed textile electrodes (3x3 cm) integrated in a sock starting with very low current amplitude followed by gradual small increases in current amplitude until induction of ankle plantar flexion, at which time-point the outcomes where measured.
Study NCT01885416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: consumption of test meal based on dairy products
Study NCT01885416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: consumption of high fat test meal without dairy products
Study NCT01885416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: consumption of high fat test meal with dairy products
Study NCT04227938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALPN-101
Description: A single dose of ALPN-101 will be administered via intravenous infusion.